NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/12/2026
Back to search
Official data from USPTO
RIBOMAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
RIBOMAB
ST13
US500000079218814Class
5, 40, 42, 44
Filing
79218814
Registration
5510495
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
03/13/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 40, 42, 44
Filing date
08/22/2017
Registration date
07/10/2018
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/24/2025
Last transaction
03/13/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
DE
Examiner
BLAZICH, JOAN MICHELE
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
B. S. (pessoa física)
BioNTech RNA Pharmaceuticals GmbH
Representatives
BARKHOFF REIMANN VOSSIUS
Technical classification
Nice Classes
Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals and veterinary preparationsof all kindspharmaceuticals and veterinary preparations for treating cancerous diseasesinfectionsautoimmune disorders and metabolic disorders; diagnostic preparations for the detection of cancerous diseasesinfectionsautoimmune disorders and metabolic disorders
Class 40
Treatment of materials and material conversioncustom manufacture of chemicals and biochemical substances; custom manufacture of chemicals and biochemical substances; custom manufacture of therapeutic preparations for the treatment of cancerous diseasesinfectionsautoimmune disorders and metabolic disorders
Class 42
Scientific research for medical and veterinary purposesin particular in respect of approaches for treating cancerous diseasesinfectionsautoimmune disorders and metabolic disorders
Class 44
Medical and veterinary services in connection with the treatment of cancerous diseasesinfectionsautoimmune disorders and metabolic disorders
Publications
History of USPTO decisions and trademark events.
31 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
03/11/2026
INPC
INVALIDATION PROCESSED
03/11/2026
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
09/24/2025
C71T
CANCELLED SECTION 71
01/24/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/15/2022
CHLD
CHANGE OF OWNER RECEIVED FROM IB
12/31/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/09/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/22/2018
FIMP
FINAL DISPOSITION PROCESSED
10/22/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/10/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
07/10/2018
PUBO
PUBLISHED FOR OPPOSITION
04/24/2018
NPUB
NOTICE OF PUBLICATION
04/04/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/20/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/13/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/13/2018
ALIE
ASSIGNED TO LIE
03/09/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/26/2018
RFNT
REFUSAL PROCESSED BY IB
01/27/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/08/2018
RFRR
REFUSAL PROCESSED BY MPU
01/08/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/19/2017
CNRT
NON-FINAL ACTION WRITTEN
12/18/2017
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
12/14/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/05/2017
CNRT
NON-FINAL ACTION WRITTEN
12/04/2017
DOCK
ASSIGNED TO EXAMINER
11/27/2017
MAFR
APPLICATION FILING RECEIPT MAILED
10/27/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/23/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/19/2017
Continuous trademark protection
Get notified about every new filing that threatens RIBOMAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.